Intranasal glucocorticoid delivery: Competition between local and systemic effects

S.T.P. Pharma Sciences

Volumn 12, Issue 1, 2002, Pages 23-31

  Hochhaus, G ^a   Sahasranaman, S ^a   Derendorf, H ^a   Mollmann H ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Glucocorticoids; Intranasal; Local effects; Phaarmacokinetics; Systemic effects.

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; REVIEW; SYSTEMIC DISEASE; TREATMENT PLANNING;

EID: 0036146716     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Intranasal corticosteroids for allergic rhinitis: How do different agents compare?
2. Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis
3. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis
4. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis
5. Mometasone furoate. A review of its intranasal use in allergic rhinitis
6. Flunisolide: A review of its pharmacological properties and therapeutic efficacy in rhinitis
7. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis
8. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis
9. Correlation between chemical structure, receptor binding, and biological activity of some novel, high active, 16a, 17a acetal substituted glucocorticoids
10. Identification of glucocorticoid receptors in normal and neoplastic human lungs
11. Affinities of glucocorticoids for glucocorticoid receptors in the human lung
12. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Ioteprednol etabonate
13. An in vitro comparison of commonly-used topical glucocorticoid preparations
14. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids
15. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model
16. Affinities of glucocorticoids for glucocorticoid receptors in the human lung
17. Binding affinities of rimexolone (ORG6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue
18. Lipophilicity and receptor affinity of glucocorticoids
19. Activiation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate
20. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids
21. Pharmacokinetics/pharmacodynamics of budesonide foam after single and multiple dosing
22. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate
23. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration
24. Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation
25. Plasma protein binding of betamethasone-3H, dexamethasone-3H and cortisol-14C, a comparative study
26. In vitro studies on the binding of cloprednol to human plasma proteins
27. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid
28. Anotomy and physiology
29. Systemic availability of budesonide after nasal administration of three different formulations: Pressurized aerosol, aqueous pump spray, and powder
30. The nasal distribution of metered dose inhalers
31. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids
32. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium
33. Biodistribution and kinetics of nasal carbon-11 -triamcinolone acetonide
34. Nasal distribution of budesonide inhaled via a powder inhaler
35. Dose optimization based on pharmacokinetic/pharmacodynamic modeling
36. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration
37. Flunisolide metabolism and dynamics of a metabolite
38. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects
39. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers
40. Systemic effects of intranasal steroids: An endocrinologist's perspective
41. Factors involved in the pulmonary targeting of inhaled glucocorticoids: The use of pharmacokinetic/dynamic simulations
42. Pharmacokinetics of fluticasone propionate (FP) after inhalation into the lung and nose
43. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations
44. Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide
45. Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism
46. Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone
47. Mathematical modeling of cortisol circadian rhythm and cortisol suppression
48. Do intranasal corticosteroids affect childhood growth?
49. A comparitive study of the effects ofintranasal triamcinolone acetonide aerosol (ITAA) and prednisone on adrenocortical function
50. A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis
51. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis
52. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis
53. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity
54. Lack of HPA axis suppression following 36 days of intransal mometasone furoate
55. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children
56. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis
57. Systemic effects of two nasally administered glucocorticosteroids
58. Nasal bioavailability and systemic effects of the glucocorticoidd budesonide in man
59. A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis
60. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis
61. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function
62. The effect of intranasal and inhaled corticosteroids in healthy volunteers on the number of circulating lymphocytes and lymphocyte subsets
63. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids
64. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray (Vancenase AQ [VNS] on long term growth in children
65. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide
66. Assessing the effect of intranasal steroids on growth